Bionova Scientific, a CDMO, is getting into the superior remedy manufacturing house by putting in its third FlexFactory manufacturing platform whereas sustaining their core monoclonal antibody (mAb) enterprise. Bionova will even use Cytiva’s Quick Trak course of improvement companies to assist advance their entry into genomic medicines.
“Utilizing Cytiva’s end-to-end options, we’ll have an distinctive platform to help the manufacture of genomic medicines,” says Fabio Fonseca, PhD, senior director, pDNA course of improvement, Bionova Scientific. “Along with our workforce and expertise stack, we’re nicely positioned to ship plasmid DNA with velocity, high quality and affected person security.”
The FlexFactory platform for superior therapies affords substantial advantages that cut back enterprise dangers, improve operational velocity, quicker product ramp-up, and improve flexibility, based on Ludovic Brellier, president of {hardware} options, Cytiva. Its built-in compliance options and strong quality control helps enhance regulatory adherence and decrease manufacturing points, he continues, whereas its modular setup permits speedy adaptation to market shifts.
Bionova’s facility in The Woodlands, TX celebrated its grand opening on Might 29, with the brand new FlexFactory slated for supply in Q3 2025. For extra info on the FlexFactory manufacturing platform, click on right here.
